On Mar. 31, 2020, VBI Vaccines announced a collaboration with the National Research Council of Canada (NRC) to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).